Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINE® compound CX717 achieved statistical significance (p = 0.005) over placebo on the primary endpoint measure of spontaneous basal respiration without affecting opioid-induced analgesia.
Popularity: unranked [?]
Related posts:
- Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder
- 6-Week Study In Adults With Major Depressive Disorder Evaluates Effectiveness Of Adjunctive Aripiprazole Therapy With Antidepressants
- Psylin Neurosciences Commences Development Of Compound For Depression
- Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression
- Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone
Comments
No Responses to “AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression Study In Germany”